APPLICATION NUMBER:

206940Orig1s000

MICROBIOLOGY / VIROLOGY REVIEW(S)
DATE: 31 July 2014

TO: NDA 206940

FROM: Bryan S. Riley, Ph.D.
Team Leader (Acting)
OPS/New Drug Microbiology Staff

THROUGH: John W. Metcalfe, Ph.D.
Senior Review Microbiologist
OPS/New Drug Microbiology Staff

cc: Jennifer Sarchet RN, BSN
LCDR, U.S. Public Health Service Corps
Regulatory Project Manager
OND/DGIEP

SUBJECT: Product Quality Microbiology assessment of Microbial Limits for (Eluxadoline) Tablets [Submission Date: 26 June 2014]

The Microbial Limits specification for (b)(4) is acceptable from a Product Quality Microbiology perspective. Therefore, this submission is recommended for approval from the standpoint of product quality microbiology.

(b)(4) is a Tablet for oral administration.

The drug product is tested for Microbial Limits at release using a method consistent with USP Chapter <61> (Microbiological Examination of Non-sterile Products: Microbial Enumeration Tests) and <62> (Microbiological Examination of Non-sterile Products: Tests for Specified Microorganisms). The Microbial Limits acceptance criteria are consistent with USP Chapter <1111> (Microbiological Examination of Non-sterile Products: Acceptance Criteria for Pharmaceutical Preparations and Substances for Pharmaceutical Use).
MEMORANDUM

Table 1 – Microbial Limits Specifications

<table>
<thead>
<tr>
<th>Test</th>
<th>Acceptance Criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Aerobic Microbial Count (USP &lt;61&gt;)</td>
<td>NMT 10^6 CFU/g</td>
</tr>
<tr>
<td>Total Yeast and Mold Count (USP &lt;61&gt;)</td>
<td>NMT 10^2 CFU/g</td>
</tr>
<tr>
<td>E. coli (USP &lt;62&gt;)</td>
<td>Absent in 10^6 g</td>
</tr>
</tbody>
</table>

The Microbial Limits test methods were verified to be appropriate for use with the drug product following procedures consistent with those in USP Chapter <61> and <62>.

The drug product will also be tested for Microbial Limits annually as part of the post-approval stability protocol.

ADEQUATE

Reviewer Comments – The microbiological quality of the drug product is controlled via a suitable testing protocol.

END
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

BRYAN S RILEY
08/01/2014

JOHN W METCALFE
08/01/2014

I concur.